Search Tag: semaglutide

2024 24 Jul

  Semaglutide emerged as the most frequently prescribed GLP-1 receptor agonist (GLP-1RA) in 2023 by a significant margin. A nationwide study revealed a substantial rise in new GLP-1RA prescriptions over the past decade, especially since 2020.    While semaglutide dominated prescriptions in 2023, the study also noted a shift in the patient...Read more

2023 05 Sep

Novo Nordisk, the Danish pharmaceutical giant behind the weight-loss medication Wegovy (active ingredient - semaglutide), has become Europe's most valuable company, dethroning the French luxury conglomerate LVMH.   Following the successful launch of Wegovy in the U.K., the company's shares saw a significant uptick in value. As trading closed...Read more